Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 13/20 | 1.00 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.54 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7550918 | 0.89 | LIPE (0.81) | LIPEPRMT5WDR77SMN1; SMN2HPGD | |
| SCHEMBL7550712 | 0.89 | LIPE (0.80) | LIPEPRMT5WDR77NPC1RAB9A | |
| SCHEMBL7549145 | 0.89 | LIPE (1.00) | LIPEDRD2SMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL7557024 | 0.89 | LIPE (1.00) | LIPEPRMT5WDR77 | |
| SCHEMBL7555453 | 0.89 | LIPE (0.80) | LIPEPRMT5WDR77DRD2NPC1 | |
| Hydrochloric Acid SCHEMBL7555439 | 0.88 | LIPE (0.78) | LIPEPRMT5WDR77DRD2NPC1 | |
| SCHEMBL7551256 | 0.86 | LIPE (1.00) | LIPEPRMT5WDR77NPC1RAB9A | |
| SCHEMBL7550743 | 0.86 | LIPE (0.74) | LIPEPRMT5WDR77SMN1; SMN2NPC1 | |
| SCHEMBL7557011 | 0.86 | LIPE (0.74) | LIPEPRMT5WDR77DRD2 | |
| SCHEMBL7556635 | 0.84 | LIPE (0.75) | LIPEPRMT5WDR77DRD2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082254-A1 | Compounds for treating disorders where a decreased level of plasma FFA is desired | NOVO NORDISK A/S (DK) | 2002-06-27 | — | — | US | disclosed |
| WO-2001087843-A1 | COMPOUNDS FOR TREATING DISORDERS WHERE A DECREASED LEVEL OF PLASMA FFA IS DESIRED | NOVO NORDISK A/S (DK) | 2001-11-22 | — | — | WO | disclosed |
| EP-0671388-A1 | (Pyrrolidinyl)phenyl carbamates and intermediate compounds, processes for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1995-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082254-A1 | Compounds for treating disorders where a decreased level of plasma FFA is desired | FABP1, FFAR2, FFAR1 | LIPE 109/4885PRMT5 1897/4885WDR77 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.